Emeline J RIBOT

Dr. Emeline J RIBOT

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2011 in Molecular Cancer Research
Verified
Journal Article
Closed access
PDF file
PMPatricia M. McGowan
Patricia M. McGowan
CSCarmen Simedrea
Carmen Simedrea
EREmeline J RIBOT
Emeline J RIBOT
PFPaula J. Foster
Paula J. Foster
DPDiane Palmieri
Diane Palmieri
ACAnn F. Chambers
Ann F. Chambers
Brain metastasis from breast cancer is an increasingly important clinical problem. Here we assessed the role of CD44hi/CD24lo cells and pathways that regulate them, in an experimental model of brain metastasis. Notch signaling (mediated by γ-secretase) has been shown to contribute to maintenance of the cancer stem cell (CSC) phenotype. Cells sorted for a reduced stem-like phenotype had a reduced ability to form brain metastases compared with unsorted or CD44hi/CD24lo cells (P < 0.05; Kruskal–Wallis). To assess the effect of γ-secretase inhibition, cells were cultured with DAPT and the CD44/CD24 phenotypes quantified. 231-BR cells with a CD44hi/CD24lo phenotype was reduced by about 15% in cells treated with DAPT compared with DMSO-treated or untreated cells (P = 0.001, ANOVA). In vivo, mice treated with DAPT developed significantly fewer micro- and macrometastases compared with vehicle treated or untreated mice (P = 0.011, Kruskal–Wallis). Notch1 knockdown reduced the expression of CD44hi/CD24lo phenotype by about 20%. In vitro, Notch1 shRNA resulted in a reduction in cellular growth at 24, 48, and 72 hours time points (P = 0.033, P = 0.002, and P = 0.009, ANOVA) and about 60% reduction in Matrigel invasion was observed (P < 0.001, ANOVA). Cells transfected with shNotch1 formed significantly fewer macrometastases and micrometastases compared with scrambled shRNA or untransfected cells (P < 0.001; Kruskal–Wallis). These data suggest that the CSC phenotype contributes to the development of brain metastases from breast cancer, and this may arise in part from increased Notch activity. Mol Cancer Res; 9(7); 834–44. ©2011 AACR.

13 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JGJeffrey M. Gaudet
Jeffrey M. Gaudet
EREmeline J RIBOT
Emeline J RIBOT
YCYuhua Chen
Yuhua Chen
KGKyle M. Gilbert
Kyle M. Gilbert
PFPaula J. Foster
Paula J. Foster
In this study we used cellular magnetic resonance imaging (MRI) to detect mesenchymal stem cells (MSC) labeled with a Fluorine-19 (19F) agent. 19F-MRI offers unambiguous detection and in vivo quantification of labeled cells. We investigated two common stem cell transplant mouse models: an immune competent, syngeneic transplant model and an immune compromised, xenograft transplant model. 19F labelled stem cells were implanted intramuscularly into the hindlimb of healthy mice. The transplant was then monitored for up to 17 days using 19F-MRI, after which the tissue was excised for fluorescence microscopy and immunohistochemisty. Immediately following transplantation, 19F-MRI quantification correlated very well with the expected cell number in both models. The 19F signal decreased over time in both models, with a more rapid decrease in the syngeneic model. By endpoint, only 2/7 syngeneic mice had any detectable 19F signal. In the xenograft model, all mice had detectable signal at endpoint. Fluorescence microscopy and immunohistochemistry were used to show that the 19F signal was related to the presence of bystander labeled macrophages, and not original MSC. Our results show that 19F-MRI is an excellent tool for verifying the delivery of therapeutic cells early after transplantation. However, in certain circumstances the transfer of cellular label to other bystander cells may confuse interpretation of the long-term fate of the transplanted cells.

1 November 2011 in Investigative Radiology
Verified
Journal Article
Closed access
DPDean B. Msc Percy
Dean B. Msc Percy
EREmeline J RIBOT
Emeline J RIBOT
YCYuhua Bsc Chen
Yuhua Bsc Chen
CMCatherine BRT Diploma McFadden
Catherine BRT Diploma McFadden
CSCarmen Bh Simedrea
Carmen Bh Simedrea
PFPaula Foster
Paula Foster
Objectives: The current lack of efficacy for any chemo- or molecular therapeutic in the treatment of brain metastases is thought to be due, in part, to the heterogeneous permeability of the blood-brain-barrier (BBB). Little is known about how heterogeneous permeability develops, or how it varies among individual metastases. Understanding the BBB's role in metastasis will be crucial to the development of new, more effective therapies. In this article, we developed the first magnetic resonance imaging-based strategy to detect and measure the volumes of BBB permeable and nonpermeable metastases and studied the development of altered BBB permeability in metastases in vivo, over time in a mouse model of breast cancer metastasis to the brain. Materials and Methods: Animals bearing human experimental brain metastases of breast cancer (231-BR cells) were imaged, using 3-dimensional balanced steady-state free precession to visualize total metastases, and contrast-enhanced T1-weighted spin echo with gadopentetic acid (Gd-DTPA) to visualize which of these displayed contrast enhancement, as Gd-DTPA leakage is indicative of altered BBB permeability. Results: Metastases detected 20 days after injection showed no Gd-DTPA enhancement. At day 25, 6.1% ± 6.3% (mean ± standard deviation) of metastases enhanced, and by day 30, 28.1% ± 14.2% enhanced (P < 0.05). Enhancing metastases (mid: 0.14 ± 0.18 mm3, late: 0.24 ± 0.32 mm3) had larger volumes than nonenhancing (mid: 0.04 ± 0.04 mm3, late: 0.09 ± 0.09 mm3, P < 0.05); however, there was no significant difference between the growth rates of the 2. Conclusions: A significant number of brain metastases were uniformly nonpermeable, which highlights the need for developing treatment strategies that can overcome the permeability of the BBB. The model developed herein can provide the basis for in vivo evaluation of both BBB permeable and nonpermeable metastases response to therapy.

19 May 2007 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
PVPierre Voisin
Pierre Voisin
EREmeline J RIBOT
Emeline J RIBOT
SMSylvain Miraux
Sylvain Miraux
ABAnne-Karine Bouzier-Sore
Anne-Karine Bouzier-Sore
JLJean-François Lahitte
Jean-François Lahitte
Marie-Helene DELVILLEMarie-Helene DELVILLE
Marie-Helene DELVILLE

26 October 2012 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Closed access
PDF file
GSGabrielle M. Siegers
Gabrielle M. Siegers
EREmeline J RIBOT
Emeline J RIBOT
AKArmand Keating
Armand Keating
PFPaula Foster
Paula Foster

29 July 2008 in Journal of Magnetic Resonance Imaging
Verified
Journal Article
Open access
PDF file
SMSylvain Miraux
Sylvain Miraux
PMPhilippe Massot
Philippe Massot
EREmeline J RIBOT
Emeline J RIBOT
JFJean‐Michel Franconi
Jean‐Michel Franconi
ETEric Thiaudiere
Eric Thiaudiere
Purpose: To examine the ability of TrueFISP imaging for evaluating tumor size in mouse brain at high field.Materials and Methods: Brains of healthy and glioma‐implanted nude mice were imaged at 4.7T and 9.4T. 3D imaging was performed with TrueFISP and T2w‐RARE. Radiofrequency pulses with alternating phase and the sum‐of‐squares reconstruction method were used in TrueFISP imaging. The contrast‐to‐noise ratio (CNR) was evaluated in healthy and in tumoral brain regions.Results: Banding artifact was correctly suppressed in TrueFISP images thanks to the method used. The signal‐to‐noise ratio (SNR) and CNR were comparable in TrueFISP and T2w‐RARE images at 4.7T, but acquisition was around 4 times shorter with TrueFISP. Tumor was well detected at 4.7T with TrueFISP, but CNR between tumor and healthy tissue was low at 9.4T.Conclusion: TrueFISP is efficient and fast to perform brain imaging at 4.7T. Multiple TrueFISP acquisitions with phase‐cycled radiofrequency (RF) pulses and sum‐of‐squares reconstruction allow suppression of banding artifact. Tumoral regions were well detected and the method allows longitudinal studies of tumor growth. J. Magn. Reson. Imaging 2008;28:497–503.